RecruitingNot ApplicableNCT06962033

PRIDE III Prison Interventions and HIV Prevention Collaboration

Sponsor

Yale University

Enrollment

300 participants

Start Date

Nov 5, 2024

Study Type

INTERVENTIONAL

Conditions

Opioid Use HIV

Summary

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Eligibility

Min Age: 18 Years

Inclusion Criteria22

Aim 1:
Quantitative surveys for prison OAT providers
Being 18 years or older
Being currently assigned and working as a probation OAT provider for a probation site
ECHO procedures
Aim 2:
Quantitative surveys for people in probation
Being 18 years or older
Screen yes to opioid injection on the online screener questionnaire
Currently in probation
Quantitative surveys for probation and prison officers
Being 18 years or older
Being currently assigned and working as a probation or prison officer at a probation site
Focus Groups (People in probation)
Being 18 years or older
Screen yes to opioid injection criteria on the online screener
Currently in probation
Focus Groups (Probation and prison officers)
Being 18 years or older
Being currently assigned and working as a probation or prison officer at a probation
Has more than 3 months of field experience
Works at a probation site within 25 kilometers of an OAT site

Exclusion Criteria1

Interventions

BEHAVIORALOpioid Agonist Therapy

Opioid Agonist Therapy (OAT) as HIV prevention

Locations(5)

Yale University

New Haven, Connecticut, United States

Alternative Georgia

Tbilisi, Georgia

AIDS Foundation East-West (AFEW)

Bishkek, Kyrgyzstan

NGO AFI

Chisinau, Moldova

Institute for International Health and Education (IIHE)

Dushanbe, Tajikistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06962033

Related Trials

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

NCT054190241 location

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT071993352 locations